AU2022212108A1 - Formulations - Google Patents

Formulations Download PDF

Info

Publication number
AU2022212108A1
AU2022212108A1 AU2022212108A AU2022212108A AU2022212108A1 AU 2022212108 A1 AU2022212108 A1 AU 2022212108A1 AU 2022212108 A AU2022212108 A AU 2022212108A AU 2022212108 A AU2022212108 A AU 2022212108A AU 2022212108 A1 AU2022212108 A1 AU 2022212108A1
Authority
AU
Australia
Prior art keywords
composition
formulation
pilocarpine
produced
thickener
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022212108A
Other languages
English (en)
Other versions
AU2022212108A9 (en
Inventor
Xiaojun Michael Liu
James Jane-Guo Shiah
Gabriella SZEKELY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaukos Corp
Original Assignee
Glaukos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaukos Corp filed Critical Glaukos Corp
Publication of AU2022212108A1 publication Critical patent/AU2022212108A1/en
Publication of AU2022212108A9 publication Critical patent/AU2022212108A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2022212108A 2021-01-28 2022-01-28 Formulations Pending AU2022212108A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163142889P 2021-01-28 2021-01-28
US63/142,889 2021-01-28
PCT/US2022/014317 WO2022165178A1 (en) 2021-01-28 2022-01-28 Formulations

Publications (2)

Publication Number Publication Date
AU2022212108A1 true AU2022212108A1 (en) 2023-08-17
AU2022212108A9 AU2022212108A9 (en) 2024-05-09

Family

ID=82494246

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022212108A Pending AU2022212108A1 (en) 2021-01-28 2022-01-28 Formulations

Country Status (6)

Country Link
US (3) US11872213B2 (cg-RX-API-DMAC7.html)
EP (1) EP4284362A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024505517A (cg-RX-API-DMAC7.html)
AU (1) AU2022212108A1 (cg-RX-API-DMAC7.html)
CA (1) CA3210064A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022165178A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220160668A1 (en) 2020-11-23 2022-05-26 Sight Sciences, Inc. Formulations and methods for treating conditions of the eye
US11872213B2 (en) 2021-01-28 2024-01-16 Glaukos Corporation Formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5422116A (en) * 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
ES2752008T3 (es) * 2009-10-30 2020-04-02 Intratus Inc Métodos y composiciones para la liberación sostenida de fármacos
US9421199B2 (en) * 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US11052094B2 (en) * 2015-05-29 2021-07-06 Sydnexis, Inc. D2O stabilized pharmaceutical formulations
US20190262290A1 (en) * 2016-10-12 2019-08-29 Ps Therapies Ltd Drug vehicle compositions and methods of use thereof
CN110996904A (zh) * 2017-05-19 2020-04-10 奥古根有限公司 眼用组合物及使用方法
JP6946575B2 (ja) * 2018-04-24 2021-10-06 アラーガン、インコーポレイテッドAllergan,Incorporated 眼の状態の治療のためのピロカルピン塩酸塩の使用
US11872213B2 (en) 2021-01-28 2024-01-16 Glaukos Corporation Formulations
WO2024026365A1 (en) * 2022-07-26 2024-02-01 Glaukos Corporation Ophthalmic topical cream formulations and uses thereof

Also Published As

Publication number Publication date
US20220233506A1 (en) 2022-07-28
WO2022165178A1 (en) 2022-08-04
EP4284362A4 (en) 2024-12-25
US20260124179A1 (en) 2026-05-07
US11872213B2 (en) 2024-01-16
WO2022165178A9 (en) 2022-10-13
US20240115551A1 (en) 2024-04-11
CA3210064A1 (en) 2022-08-04
AU2022212108A9 (en) 2024-05-09
US12533344B2 (en) 2026-01-27
JP2024505517A (ja) 2024-02-06
EP4284362A1 (en) 2023-12-06

Similar Documents

Publication Publication Date Title
US20260124179A1 (en) Formulations
US20250381215A1 (en) High elasticity hyaluronan compositions and methods of use thereof
Cheng et al. Sustained delivery of latanoprost by thermosensitive chitosan–gelatin-based hydrogel for controlling ocular hypertension
WO2023225551A1 (en) Novel applications of zwitterions in ophthalmic topical cream compositions and preparations
CN104906580A (zh) 无刺激性眼科聚维酮碘组合物
WO2016016908A1 (en) Method of increasing bioavailability and/or prolonging ophthalmic action of a drug
WO2020219707A1 (en) Compositions and methods for treatment of ocular conditions
EP2249765B1 (en) Dapsone to treat rosacea
CN101977630B (zh) 眼药组合物
CA2851492A1 (en) Ophthalmic gel compositions
US12576126B2 (en) Nanoemulsion ophthalmic composition comprising cyclosporine and menthol, and preparation method thereof
CN102018656A (zh) 含有效成分拉坦前列素的眼用凝胶剂及其制备方法
JP2003055201A (ja) ビタミンa類含有可溶化組成物及びビタミンa類の安定化方法
KR100938233B1 (ko) 프로스타글란딘계 점안용 조성물과 그의 제조 방법
RU2806029C2 (ru) Композиции, обеспечивающие повышенный комфорт для глаз
WO2024240216A9 (zh) 一种有效延缓及治疗近视的药物组合物
Arif et al. THE EFFECTS OF DIFFERENT PHYSICAL PROPERTIES OF ARTIFICIAL TEARS ON SUBJECTIVE OCULAR SENSATION
HK40128453A (en) Compositions and methods for the treatment of presbyopia
Mundada Update on Polymers for Ocular Drug Delivery
HK40109101A (en) A pharmaceutical composition for effectively delaying and treating myopia
TW202002980A (zh) 選擇性syk抑制劑之使用方法及醫藥組合物

Legal Events

Date Code Title Description
SREP Specification republished